Horinouchi H, Cho BC, Camidge DR, Goto K, et al. Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol 2025 Jan 11:S0923-7534(25)00005-5. doi: 10.1016/j.annonc.2025.
PMID: 39805351